Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBRT + Enzalutamide in Oligometastatic CRPC
NCT02685397Phase 3Active, not recruiting
- Sponsor
- Jewish General Hospital
- Start
- Oct 2016
- Primary completion
- Apr 2027
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in castration-resistant prostate cancer (CRPC), sponsored by Jewish General Hospital. Primary endpoint: Radiographic Progression-free Survival at 5 years. Started Oct 2016; status: active, not recruiting.
02
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT02685397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02685397.